Health
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies – PRNewswire
/PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the…
NEW BRUNSWICK, N.J., July 30, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and provi…
-
General23 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
General21 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell
-
Noosa News21 hours agoAlleged Gold Coast conman exposed: elderly woman’s life savings vanish in shocking scam
-
Noosa News21 hours agoHow Roosters star Eliza Lopamaua found her way to NRLW